IAGARU ANDREI

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

Phase 2

Recruiting

Conditions: Parathyroid Adenoma

Interventions: Drug: 18Fluorocholine

First Posted Date: 2023-06-07

Last Posted Date: 2024-04-17

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 100

Registration Number: NCT05891769

Locations: 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States

Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Head-and-neck Squamous Cell Carcinoma

Interventions: Drug: 89Zr-panitumumab IV
Drug: Panitumumab

First Posted Date: 2022-06-21

Last Posted Date: 2024-10-31

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 60

Registration Number: NCT05423197

Locations: 🇺🇸
Stanford Cancer Institute, San Francisco, California, United States

Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer

Phase 1

Recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: 111I-n panitumumab
Procedure: Single photon emission computed tomography/computed tomography (SPECT/CT) scans

First Posted Date: 2021-04-12

Last Posted Date: 2025-05-06

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 28

Registration Number: NCT04840472

Locations: 🇺🇸
Stanford University, Stanford, California, United States

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: 68-Ga RM2.
Drug: 68-Ga PSMA11
Device: PET/MRI

First Posted Date: 2020-02-11

Last Posted Date: 2024-02-01

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 4

Registration Number: NCT04264208

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: 68-Ga RM2
Drug: 68-Ga PSMA11
Device: Investigational software and coils in PET/MR Scan
Procedure: PET/MRI

First Posted Date: 2019-05-14

Last Posted Date: 2024-01-30

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 14

Registration Number: NCT03949517

Locations: 🇺🇸
Stanford University, Stanford, California, United States

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Phase 1

Completed

Conditions: Estrogen Receptor Positive
Breast Carcinoma

Interventions: Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Device: Investigational software and coils in PET/MR scan

First Posted Date: 2019-02-06

Last Posted Date: 2023-12-13

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 5

Registration Number: NCT03831711

Locations: 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

Phase 2

Completed

Conditions: Multiple Pulmonary Nodules
Pulmonary Nodule
Current Smoker
Cigarette Smoker
Former Smoker

Interventions: Diagnostic Test: Computed Tomography
Drug: Fludeoxyglucose F-18
Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392
Diagnostic Test: Positron Emission Tomography (PET/CT)

First Posted Date: 2019-01-31

Last Posted Date: 2025-04-09

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 15

Registration Number: NCT03824535

Locations: 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: 68Ga RM2
Drug: 68Ga-PSMA-11
Device: Investigational PET scanner coils and software

First Posted Date: 2019-01-18

Last Posted Date: 2024-01-11

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 14

Registration Number: NCT03809078

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck
Carcinoma of the Head and Neck

Interventions: Drug: Panitumumab-IRDye800
Drug: 89-Zirconium (Zr-89) Panitumumab
Device: Pinpoint IR IR9000 fluorescence imaging system (FIS)
Device: SPY-PHI IR9000 fluorescence imaging system (FIS)
Device: Explorer Air camera
Device: PDE-NEO II camera
Device: FIS-00 fluorescence imaging system (FIS)
Device: Da Vinci Firefly Imaging System
Device: IGP-ELVIS-v4 Macroscopic Specimen Imager
Device: Vevo 3100 LAZR-X
Device: Pearl Triology Imaging System
Device: Odyssey CLx Imaging System
Device: Leica fluorescence microscope

First Posted Date: 2018-11-07

Last Posted Date: 2023-05-19

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 14

Registration Number: NCT03733210

Locations: 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Carcinoma
PSA Progression
Prostate Adenocarcinoma

Interventions: Drug: Gallium Ga 68 DOTA-NeoBOMB1
Device: Gallium Ga 68 PSMA-R2

First Posted Date: 2018-10-09

Last Posted Date: 2024-01-30

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 27

Registration Number: NCT03698370

Locations: 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

Home Terms & Conditions Privacy Policy